心血管治疗公司提名蒂莫西·加尼特博士为其董事会成员-动脉网

Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors

INN 等信源发布 2025-04-29 20:25



可切换为仅中文







Investing News Network

投资新闻网

April 29, 2025

2025年4月29日

Former Chief Medical Officer of Eli Lilly brings more than thirty years of pharmaceutical industry experience

礼来公司前首席医疗官，拥有三十多年的制药行业经验。

Cardiol Therapeutics

心脏治疗学

Inc. (NASDAQ: CRDL) (

公司（纳斯达克股票代码：CRDL）（

TSX: CRDL

) ('Cardiol' or the 'Company'), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced that pharmaceutical industry veteran Timothy J. Garnett, M.D., has been nominated to stand for election to the Company's Board of Directors at its 2025 Annual General Meeting of shareholders to be held on May 28, 2025..

）（“Cardiol”或“公司”），一家专注于开发抗炎和抗纤维化疗法以治疗心脏病的临床阶段生命科学公司，今天宣布，制药行业资深人士蒂莫西·J·加内特博士已被提名在2025年5月28日举行的年度股东大会上竞选公司董事会董事。

Dr. Garnett is a distinguished pharmaceutical industry executive with over 30 years' experience, including two decades at Eli Lilly and Company, where he served as Chief Medical Officer from 2008 until his retirement in 2021. During his tenure at Eli Lilly, he led the successful development of therapeutics in women's health, endocrinology, and neuroscience, resulting in multiple global commercial launches.

加内特博士是一位拥有超过 30 年经验的杰出制药行业高管，包括在礼来公司工作的二十年，他曾于 2008 年至 2021 年退休期间担任首席医学官。在礼来公司任职期间，他领导了女性健康、内分泌学和神经科学领域治疗药物的成功开发，实现了多次全球商业发布。

Dr. Garnett has played a key role in the successful development of numerous drugs across both early- and late-stage clinical development. He has broad experience leading clinical development, portfolio management, medical affairs, regulatory strategy, and safety functional areas, and has a strategic understanding of the evolving metabolic therapy landscape..

加内特博士在众多药物的早期和晚期临床开发的成功中发挥了关键作用。他在领导临床开发、产品组合管理、医学事务、监管策略和安全功能领域拥有广泛经验，并对不断发展的代谢治疗领域有战略性的理解。

'We are pleased to nominate Dr. Garnett for election to our Board of Directors, as we mark a significant milestone with the recent initiation of patient enrollment in our pivotal Phase III MAVERIC trial,' stated Guillermo Torre-Amione, M.D., Ph.D., Chair of

“我们很高兴提名加内特博士当选为我们董事会成员，因为我们最近在关键的三期MAVERIC试验中开始了患者招募，这标志着一个重要的里程碑，”吉列尔莫·托雷-阿米奥内医学博士、哲学博士、主席表示。

Cardiol Therapeutics

卡迪奥治疗公司

. 'Dr. Garnett brings a wealth of industry experience and strategic vision, along with exceptional expertise in clinical development. His proven track record in guiding several drugs through regulatory approval and successful commercial launch will be instrumental in achieving our goal of making a meaningful difference for people living with underserved heart disease.'.

“加内特博士带来了丰富的行业经验与战略视野，以及在临床开发方面的卓越专长。他在指导多种药物通过监管审批并成功实现商业化上市方面有着良好的记录，这将对我们实现为患有服务不足的心脏病人群带来有意义改变的目标起到至关重要的作用。”

Dr. Garnett currently serves as Chair of Ophirex and a Director of MapLight Therapeutics. In addition, he is a member of the Advisory Panel of Cambridge Innovation Capital and an equity partner at Recode Health Ventures LLC. Dr. Garnett holds a Bachelor of Medicine and Bachelor of Surgery (MBBS) from St.

加内特博士目前担任Ophirex的主席和MapLight Therapeutics的董事。此外，他是剑桥创新资本顾问小组的成员，也是Recode Health Ventures LLC的股权合伙人。加内特博士拥有圣大学的医学学士和外科学士（MBBS）学位。

George's, University of London. He is a Fellow of both the Faculty of Pharmaceutical Medicine (FFPM), and the Royal College of Obstetricians and Gynaecologists (FRCOG)..

伦敦大学乔治学院。他是医药学院 (FFPM) 和皇家妇产科医学院 (FRCOG) 的院士。

About

关于

Cardiol Therapeutics

心脏治疗公司

Cardiol Therapeutics

心脏治疗公司

Inc.

公司

(NASDAQ: CRDL) (

（纳斯达克：CRDL）（

TSX: CRDL

)

is a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small molecule drug candidate, CardiolRx™ (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease.

是一家临床阶段的生命科学公司，专注于开发用于治疗心脏病的抗炎和抗纤维化疗法。该公司主要的小分子候选药物CardiolRx™（大麻二酚）口服溶液经过制药工艺生产，目前正处于临床开发阶段，用于治疗心脏病。

It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure..

人们认识到，大麻二醇抑制炎症小体通路的激活，这是一种已知在心肌炎、心包炎和心力衰竭相关的炎症和纤维化的发展和进展中起重要作用的细胞内过程。

Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration ('US FDA') to conduct clinical studies to evaluate the efficacy and safety of CardiolRx™ in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease of the pericardium which is associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, and results in physical limitations, reduced quality of life, emergency department visits, and hospitalizations, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299).

Cardiol 已获得美国食品药品监督管理局（US FDA）的新药临床试验申请授权，以开展临床研究，评估 CardiolRx™ 在两种影响心脏的疾病中的疗效和安全性：复发性心包炎和急性心肌炎。MAVERIC 计划针对复发性心包炎，这是一种心包的炎症性疾病，伴有包括严重胸痛、呼吸急促和疲劳在内的症状，导致身体受限、生活质量下降、急诊就诊和住院。该计划包括已完成的 II 期 MAvERIC-Pilot 研究（NCT05494788）和正在进行的 III 期 MAVERIC 试验（NCT06708299）。

The ongoing ARCHER trial (NCT05180240) is a Phase II study in acute myocarditis, an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in people less than 35 years of age. The US FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, which includes recurrent pericarditis..

正在进行的ARCHER试验（NCT05180240）是一项针对急性心肌炎的二期研究，急性心肌炎是导致青壮年急性及暴发性心力衰竭的重要原因，也是35岁以下人群猝死的主要原因之一。美国食品药品监督管理局（FDA）已授予CardiolRx™治疗心包炎（包括复发性心包炎）的孤儿药资格。

Cardiol is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure - a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding $30 billion annually.

Cardiol 还在开发 CRD-38，这是一种新型的皮下注射药物配方，用于治疗心力衰竭——这是发达国家死亡和住院的主要原因之一，美国相关的医疗费用每年超过 300 亿美元。

For more information about

更多信息，请参阅

Cardiol Therapeutics

卡迪奥治疗公司

, please visit

，请访问

cardiolrx.com

。

Cautionary statement regarding forward-looking information:

关于前瞻性信息的警示声明：

This news release contains 'forward-looking information' within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are 'forward-looking information'.

本新闻稿包含适用证券法意义上的“前瞻性信息”。所有陈述，除历史事实陈述外，凡涉及Cardiol认为、预期或预计未来将会、可能、可以或也许发生的活动、事件或发展的，均为“前瞻性信息”。

Forward-looking information contained herein may include, but is not limited to statements regarding the Company's focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, the Company's intended clinical studies and trial activities and timelines associated with such activities, including the Company's plan to complete the Phase III study in recurrent pericarditis with CardiolRx, and the Company's plan to advance the development of CRD-38, a novel subcutaneous formulation of cannabidiol intended for use in heart failure.

本文包含的前瞻性信息可能包括但不限于以下陈述：公司专注于开发用于治疗心脏病的抗炎和抗纤维化疗法，公司计划开展的临床研究及试验活动及其相关时间表，包括公司计划完成CardiolRx在复发性心包炎中的III期研究，以及公司推进CRD-38（一种用于治疗心力衰竭的新型皮下注射大麻二酚制剂）开发的计划。

Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, and are not (and should not be considered to be) guarantees of future performance.

本文所含前瞻性信息反映了Cardiol基于当前可获得的信息对其当前的期望或信念，该信息基于某些假设，并受多种已知和未知的风险、不确定性及其他因素的影响，这些因素可能导致实际事件或结果与前瞻性信息中明示或暗示的任何未来结果、业绩或成就存在重大差异，且并非（也不应被视为）对未来业绩的保证。

These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company's Annual Information Form filed with the Canadian Securities Administrators and U.S. Securities and Exchange Commission on March 31, 2025, available on SEDAR+ at .

这些风险和不确定性以及其他因素包括公司在2025年3月31日向加拿大证券管理员和美国证券交易委员会提交的年度信息表中提及的风险和不确定性，可在SEDAR+上查阅。

sedarplus.ca

and EDGAR at

和EDGAR在

sec.gov

, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes.

以及与产品商业化和临床研究相关的风险和不确定性。这些假设、风险、不确定性及其他因素应谨慎考虑，投资者不应过分依赖前瞻性信息，且该信息可能不适用于其他目的。

Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise.

本新闻稿中的任何前瞻性信息仅截至本新闻稿发布之日，除非适用的证券法要求，Cardiol不承担更新或修改此类前瞻性信息的意图或义务，无论是否由于新信息、未来事件或结果等原因。

Investors are cautioned not to rely on these forward-looking statements and are encouraged to read the Supplement, the accompanying Base Prospectus and the documents incorporated by reference therein. .

投资者应注意不要依赖这些前瞻性陈述，并鼓励其阅读补充文件、随附的基本招股说明书以及其中引用的文件。

For further information, please contact:

如需更多信息，请联系：

Trevor Burns, Investor Relations +1-289-910-0855

特雷弗·伯恩斯，投资者关系 +1-289-910-0855

trevor.burns@cardiolrx.com

To view the source version of this press release, please visit

要查看此新闻稿的源版本，请访问

https://www.newsfilecorp.com/release/250087

News Provided by Newsfile via QuoteMedia

新闻由Newsfile通过QuoteMedia提供

Cardiol Therapeutics